News

More than 110 neurotechnolgy professionals attended the 20th Annual Neurotech Leaders Forum last month. The hybrid event had a handful of attendees on site in San Francisco, but most participated via Zoom video conference. The two-day conference featured two keynote presentations: Nevro founder Konstantinos Alataris spoke on the first day, and Kernel founder Bryan Johnson spoke with NBR editor James Cavuoto on the second day [NBR Nov20 p2].

The field of psychiatry has undergone several significant transformations in recent years. One of them is the advent of neuromodulation therapies that promise to help those with treatment-resistant mood disorders. Equally important, neurotech approaches to psychiatric disorders can shed much needed light on the neurological basis of affect, as we report in our article on page 1 of this issue. But a…

The emergence of COVID-19 and the SARS-CoV-2 virus in 2020 created new opportunities for neurotech firms involved with devices treating respiratory or inflammatory disorders. In recent weeks, researchers and funding organizations have turned their attention to neurological and psychological impacts of the pandemic. In a recent study of how COVID-19 affects a patient’s brain, NIH researchers consist…

In recent years, the market for neurorehabilitation systems has matured as it has differentiated, with several new neurotech startups and research institutions now targeting a range of disorders related to stroke and brain injury. Among the conditions being targeted with neurotech therapies are dysphagia, aphasia, upper-extremity paralysis, and neurogenic pain. At the joint virtual meeting of the E…

The National Institutes of Health will fund more than 175 grants, totaling nearly $500 million, through the NIH’s Brain Research through Advancing Innovative Neurotechnologies Initiative, part of a large effort among federal and non-federal partners to use knowledge about how the brain works to develop more effective therapies for neurological disorders. “Recent discoveries and new technologies sup…

Neurotech Reports, the publisher of Neurotech Business Report, announced the winners of the 2020 Gold Electrode Awards during the 20th Annual Neurotech Leaders Forum, which took place November 16-17 in San Francisco and also via Zoom. The award for best new product went to Axonics Modulation for its R-SNM sacral nerve stimulation system. The award for most promising startup went to Synchron Inc., which is developing a novel brain-computer interface that is migrated to the brain via the cerebral vasculature.

Neurotech investigators and entrepreneurs who received funding from two key programs supported Projects Agency met with interested venture capital and strategic firm investors during the inaugural Translational Neurotech Showcase earlier this month. The invitation-only event, which was conducted via remote video conference because of the Coronavirus pandemic, took place immediately after the 20th Annual Neurotech Leaders Forum.

Neurotech Reports, the publisher of Neurotech Business Report, announced that several new and emerging neurotechnology startup firms will present at the 20th Annual Neurotech Leaders Forum on November 16-17, 2020. The hybrid event takes place at the Embassy Suites SFO and on-line via Zoom. Among the promising new neurotech firms added to the agenda are NeuroGeneces, which has developed a noninvasiv…

When we launched this publication in 2001, we predicted that the neurotechnology industry would expand significantly in the years to follow. We were certainly right about that. One of the things we were wrong about is the speed with which consumer applications of neurotechnology would emerge. We expected that computer hardware and software vendors would be chomping at the bit to integrate neural data into their products, and that frankly didn’t happen.

The neurotechnology market for treating migraine continues to show promise, despite some uncertainties caused early entrants in the space. While the commercial failures have caused concern in some patient advocacy groups, the wealth of product alternatives will likely keep this product segment on an upward trajectory. In August, eNeura Inc., a manufacturer of a handheld TMS device for treating migraine, filed for Chapter 7 bankruptcy and no other vendor has yet emerged to continue marketing their device.